Somaxon battered by second US rejection of insomnia drug
This article was originally published in Scrip
Executive Summary
The US FDA has rejected Somaxon's only drug candidate, Silenor (doxepin), stating that the drug does not show sufficient efficacy for the treatment of insomnia.